Gamma Medica to Acquire Advanced Molecular Imaging

Gamma Medica Ideas, Inc. (GM-I; Fornebu, Norway), a developer of next-generation medical imaging devices for the pre-clinical and clinical markets, has reached an agreement to acquire and merge operations with Advanced Molecular Imaging, Inc. (AMI; Sherbrooke, Canada), the developer of the first fully digital APD positron emission tomography (PET) system for pre-clinical imaging.

The combined company will provide a complete range of digital imaging technologies including APD PET and GM-I's CZT single photon emission tomography (SPECT) detector technologies, as well as the most advanced range of multiple modality imaging systems for drug discovery and medical research.

"This merger is a logical next step in the evolution of Gamma Medica that creates substantial value for the customers and shareholders of both AMI and GM-I,” said GM-I CEO and co-founder Bradley E. Patt, Ph.D. "It will create the world's first completely digital imaging suite, allowing us to provide innovative solutions to our molecular imaging customers. These solutions will streamline imaging protocols while improving data quality, resulting in a better insight into the biology and physiology underlying disease. Ultimately this should translate into more accurate diagnostic and treatment protocols.”

"The new entity is the ideal vehicle for bringing semiconductor detector technology and advanced digital signal processing to the molecular imaging market, by leveraging over 20 years of combined experience in those fields,” added Dr. Lecomte CTO of AMI.

GM-I will have offices in Los Angeles (CA, USA), Oslo (Norway), and Sherbrooke (Canada), and expects to maintain a close relationship with AMI's academic partner Université de Sherbrooke, which has developed strong expertise in PET imaging. GM-I will continue to provide its customers will its full range of systems including its FLEX Triumph Platform supporting X-PET, X-SPECT (NaI or CZT), and X-O computed tomography (CT) pre-clinical imaging sub-systems configured as single, dual, or tri-modality combinations. Following the acquisition, GM-I will also offer its LabPET APD PET (former AMI system) as a stand-alone system or in combination with any of GM-I's other subsystems.

GM-I develops novel technologies to improve patient health through early diagnosis of disease, improved patient treatment, and by enabling new drug discovery.

AMI develops medical devices and techniques to support molecular imaging of living subjects. AMI designs, manufactures, and markets advanced imaging devices targeted at the pharmaceutical pre-clinical research and clinical diagnostic markets.



Related Links:
Gamma Medica Ideas
Advanced Molecular Imaging